Pathogen diagnostic test

1. A method of detecting a Coronavirus infection in an individual,

the method comprising:

(a) providing a sample, wherein said sample comprises a biological sample from said individual and a Coronavirus synthetic RNA, wherein a nucleic acid sequence of said Coronavirus synthetic RNA differs from a naturally occurring Coronavirus nucleic acid sequence;

(b) lysing said sample, thereby producing a lysed sample;

(c) performing a reverse transcription reaction on said lysed sample to obtain a lysed, reverse transcribed sample, wherein RNA from said lysed sample is not purified before performing said reverse transcription reaction;

(d) performing an amplification reaction on said lysed, reverse transcribed sample to obtain an amplified biological sample, wherein said amplification reaction on said lysed, reverse transcribed sample is performed with a set of Coronavirus primers specific for a Coronavirus nucleic acid sequence, wherein said set of Coronavirus primers amplify said Coronavirus nucleic acid sequence and said Coronavirus synthetic RNA; and

(e) sequencing said amplified sample.

2. The method of claim 1 , further comprising providing a positive diagnosis for Coronavirus infection if sequence reads from said Coronavirus nucleic acid sequence are detected.

3. The method of claim 1 , wherein said Coronavirus infection is a SARS-Cov-2 infection.

4. The method of claim 2 , wherein said positive diagnosis for said Coronavirus infection or SARS-Cov-2 infection is provided when a ratio or a mathematical equivalent thereof of said sequence reads from said Coronavirus nucleic acid sequence to sequence reads of said Coronavirus synthetic RNA exceed about 0.1.

5. The method of claim 2 , wherein said positive diagnosis for Coronavirus infection is provided when said sequence reads from said Coronavirus nucleic acid sequence and said sequence reads of Coronavirus synthetic RNA exceed about 100 total sequence reads.

6. The method of claim 1 , wherein the method further comprises detecting an Influenza A infection, an Influenza B infection, or a combination thereof.

7. The method of claim 1 , wherein lysing said sample comprises thermal lysis.

8. The method of claim 7 , wherein said thermal lysis comprises heating said sample to a temperature of at least about 50° C.

9. The method of claim 1 , wherein said sample from said individual comprises a plurality of Coronavirus synthetic RNA sequences, wherein said plurality of Coronavirus synthetic RNA sequences comprise at least two distinct synthetic Coronavirus RNA sequences.

10. The method of claim 9 , wherein said plurality of synthetic Coronavirus RNA sequences comprise at least four distinct synthetic Coronavirus RNA nucleic acid sequences.

11. The method of claim 9 , wherein the Coronavirus synthetic RNA or the plurality of Coronavirus synthetic RNA sequences comprises an amount of guanine nucleotide that is from about 20% to about 30%, an amount of adenine nucleotide that is from about 20% to about 30%, an amount of cytosine nucleotide that is from about 20% to about 30%, an amount of uracil nucleotide that is from about 20% to about 30%.

12. The method of claim 1 , wherein said amplification reaction on said lysed sample is further performed with a set of influenza A primers specific for an influenza A nucleic acid sequence and/or a set of influenza B primers specific for an influenza B nucleic acid sequence.

13. The method of claim 1 , wherein said Coronavirus synthetic RNA is present at a concentration from about 10 copies per/reaction to about 500 copies per reaction.

14. The method of claim 1 , wherein sequencing said amplified sample comprises single molecule real-time sequencing, sequencing-by-synthesis, or ion semiconductor sequencing.

15. The method of claim 1 , wherein sequencing of said amplified sample is not Sanger sequencing.

16. The method of claim 1 , wherein sequencing said amplified sample generates at least 1 million sequence reads.